Sharescart Research Club logo

Advanced Enzyme Overview

Advanced Enzyme Technologies Ltd is engaged in commercial enterprise of manufacturing and sale of enzymes. It's geographical segments are within India and outside India. It offers solutions to industries, consisting of human healthcare and vitamins, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, natural extraction, fabric processing, leather-based processing, paper and pulp processing, biofuels, biomass processing and biocatalysts. It offers products and s...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Advanced Enzyme Key Financials

Market Cap ₹3301 Cr.

Stock P/E 24.6

P/B 2.2

Current Price ₹294.9

Book Value ₹ 136.5

Face Value 2

52W High ₹366.6

Dividend Yield 1.76%

52W Low ₹ 259.7

Advanced Enzyme Share Price

₹ | |

Volume
Price

Advanced Enzyme Quarterly Price

Show Value Show %

Advanced Enzyme Peer Comparison

Advanced Enzyme Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 158 161 158 155 146 169 167 186 185 172
Other Income 6 14 9 7 10 8 9 9 10 8
Total Income 164 175 167 162 156 177 176 195 195 180
Total Expenditure 107 107 102 103 104 114 122 129 124 123
Operating Profit 57 68 65 58 52 63 54 65 70 58
Interest 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 9 9 9 10 10 10 10
Exceptional Income / Expenses 0 0 -15 0 0 0 0 0 0 11
Profit Before Tax 48 59 40 49 42 53 43 55 60 58
Provision for Tax 13 16 10 14 9 14 17 14 15 15
Profit After Tax 35 43 30 35 33 39 27 40 45 43
Adjustments -1 -1 -2 -1 -1 -1 -0 -1 -1 -1
Profit After Adjustments 34 42 28 34 33 38 26 40 43 43
Adjusted Earnings Per Share 3.1 3.7 2.5 3.1 2.9 3.4 2.4 3.6 3.9 3.8

Advanced Enzyme Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 223 294 329 391 420 444 502 529 541 624 637 710
Other Income 3 1 3 3 6 6 9 6 25 37 33 36
Total Income 226 295 332 394 425 450 511 536 566 661 670 746
Total Expenditure 133 156 178 227 237 241 269 327 383 419 441 498
Operating Profit 93 139 154 166 188 209 241 209 183 242 229 247
Interest 9 8 4 9 5 4 3 3 3 4 5 4
Depreciation 9 9 13 18 21 26 29 35 35 35 37 40
Exceptional Income / Expenses 0 -4 0 0 0 0 0 0 -4 -15 0 11
Profit Before Tax 75 118 137 139 162 179 210 171 140 188 187 216
Provision for Tax 23 41 44 45 46 46 59 47 37 51 53 61
Profit After Tax 52 77 93 94 116 133 151 124 104 137 134 155
Adjustments -1 -1 -1 -3 -5 -4 -5 -4 2 -4 -3 -3
Profit After Adjustments 51 76 92 90 111 129 146 120 106 133 131 152
Adjusted Earnings Per Share 4.7 7 8.2 8.1 9.9 11.6 13.1 10.7 9.4 11.9 11.7 13.7

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 2% 6% 7% 11%
Operating Profit CAGR -5% 3% 2% 9%
PAT CAGR -2% 3% 0% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 7% 4% -4% NA%
ROE Average 10% 10% 12% 18%
ROCE Average 14% 14% 16% 22%

Advanced Enzyme Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 212 278 464 559 679 840 971 1089 1235 1324 1421
Minority's Interest 4 5 21 23 26 28 62 52 49 47 48
Borrowings 54 39 19 20 7 4 10 8 8 7 9
Other Non-Current Liabilities 10 17 13 23 23 35 39 51 41 37 37
Total Current Liabilities 131 111 62 99 65 60 68 60 78 106 97
Total Liabilities 412 450 583 727 805 971 1149 1260 1411 1521 1611
Fixed Assets 282 285 421 491 495 563 604 619 649 650 679
Other Non-Current Assets 25 25 18 21 23 28 29 37 39 62 53
Total Current Assets 104 140 138 211 282 376 516 604 722 810 880
Total Assets 412 450 583 727 805 971 1149 1260 1411 1521 1611

Advanced Enzyme Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 2 4 25 8 61 23 83 192 267 96 114
Cash Flow from Operating Activities 54 93 107 116 129 141 163 122 140 141 142
Cash Flow from Investing Activities -11 -5 -60 -78 -125 -44 -26 -4 -298 -65 -89
Cash Flow from Financing Activities -36 -63 -65 -2 -43 -39 -26 -49 -26 -59 -73
Net Cash Inflow / Outflow 6 26 -18 36 -39 58 111 70 -184 17 -19
Closing Cash & Cash Equivalent 4 25 8 61 23 83 192 267 96 114 94

Advanced Enzyme Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 4.68 6.97 8.2 8.08 9.95 11.58 13.06 10.7 9.45 11.92 11.72
CEPS(Rs) 5.59 7.85 9.47 10.02 12.27 14.22 16.11 14.2 12.42 15.4 15.24
DPS(Rs) 0.1 0.2 0.4 0.5 0.6 0.6 0.9 1 1 5.1 5.2
Book NAV/Share(Rs) 19.48 25.55 41.54 49.85 60.49 74.86 86.67 97.31 110.45 118.14 126.56
Core EBITDA Margin(%) 39.03 45.18 44.14 41.34 43.5 45.74 46.74 38.19 29.09 32.87 30.7
EBIT Margin(%) 36.24 41.4 41.24 37.42 39.83 41.26 42.75 32.8 26.57 30.73 30.15
Pre Tax Margin(%) 32.25 38.82 39.95 35.13 38.59 40.34 42.23 32.25 25.93 30.07 29.42
PAT Margin (%) 22.34 25.21 27.09 23.65 27.62 29.96 30.41 23.34 19.18 21.92 21.04
Cash Profit Margin (%) 26.22 28.07 30.81 28.27 32.65 35.76 36.18 29.93 25.65 27.57 26.77
ROA(%) 12.81 17.81 18 14.28 15.13 14.98 14.27 10.28 7.78 9.34 8.55
ROE(%) 27.31 31.32 25.06 18.34 18.82 17.61 16.77 12.04 8.94 10.72 9.79
ROCE(%) 25.43 35.68 31.53 25.88 24.96 23.21 22.93 16.66 12.26 14.78 13.76
Receivable days 54.62 47.26 48.73 50.01 51.02 54.83 59.04 60.03 63.55 58.11 61.31
Inventory Days 80.7 67.81 68.6 66.45 66.31 64.49 63.79 73.9 82.55 79.59 87.61
Payable days 84.8 68.75 57.95 63.8 64.17 43.59 45.81 55.08 58.32 50.47 39.61
PER(x) 0 0 50.25 26.38 18.39 12.36 26.4 26.37 24.52 29.15 23.8
Price/Book(x) 0 0 9.92 4.27 3.02 1.91 3.98 2.9 2.1 2.94 2.2
Dividend Yield(%) 0 0 0.1 0.23 0.33 0.42 0.26 0.35 0.43 1.47 1.86
EV/Net Sales(x) 0.59 0.33 14.12 6.1 4.89 3.47 7.32 5.46 4.59 6.07 4.76
EV/Core EBITDA(x) 1.42 0.7 30.12 14.33 10.91 7.37 15.22 13.83 13.56 15.62 13.28
Net Sales Growth(%) -6.82 31.67 11.99 18.85 7.31 5.81 13.03 5.49 2.13 15.4 2.09
EBIT Growth(%) 101.86 49.93 12.26 4.63 12.93 9.61 16.08 -18.19 -17.32 33.42 0.03
PAT Growth(%) 146.67 48.12 21.1 0.66 23.89 14.79 13.71 -18.17 -16.1 31.85 -2.17
EPS Growth(%) 158.29 48.78 17.64 -1.5 23.16 16.39 12.82 -18.11 -11.68 26.19 -1.69
Debt/Equity(x) 0.54 0.36 0.12 0.12 0.05 0.03 0.02 0.01 0.01 0.02 0.02
Current Ratio(x) 0.8 1.26 2.24 2.13 4.33 6.31 7.64 10 9.31 7.61 9.09
Quick Ratio(x) 0.39 0.72 1.13 1.37 3.15 4.96 6.25 8 7.71 6.22 7.47
Interest Cover(x) 9.08 16.04 31.91 16.34 32.13 44.94 82.76 58.89 41.36 46.58 41.44
Total Debt/Mcap(x) 0 0 0.01 0.03 0.02 0.02 0 0 0.01 0.01 0.01

Advanced Enzyme Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 45.92 43.62 43.49 43.02 42.95 42.93 43.08 43.08 43.07 43.04
FII 22.27 22.54 23.01 12.03 12.63 12.58 11.9 23.46 25.41 25.86
DII 6.48 6.98 7.56 8.08 8.02 8.17 8.19 8.45 6.41 5.51
Public 25.33 26.87 25.94 36.88 36.41 36.32 36.83 25.02 25.1 25.6
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Advanced Enzyme News

Advanced Enzyme Pros & Cons

Pros

  • Debtor days have improved from 50.47 to 39.61days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 43.04%.
  • Company has a low return on equity of 10% over the last 3 years.
whatsapp